References
- Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: A hitherto undescribed disease. Proc NY Pathol Soc. 1924;24:21–24.
- Moake JL, Rudy CK, Troll JH, et al. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med. 1982;307(23):1432–1435.doi:https://doi.org/10.1056/NEJM198212023072306.
- Furlan M, Robles R, Galbusera M, et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998;339(22):1578–1584.doi:https://doi.org/10.1056/NEJM199811263392202.
- Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339(22):1585–1594. doi:https://doi.org/10.1056/NEJM199811263392203.
- Scully M, Hunt BJ, Benjamin S, et al. British committee for standards in haematology. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012;158(3):323–335.doi:https://doi.org/10.1111/j.1365-2141.2012.09167.x.
- Mariotte E, Azoulay E, Galicier L. et al. Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): A cross-sectional analysis of the French national registry for thrombotic microangiopathy. Lancet Haematol. 2016;3:e237–e245. doi:https://doi.org/10.1016/S2352-3026(16)30018-7.
- Kremer Hovinga JA, Vesely SK, Terrell DR, Lämmle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2010;115(8):1500–1511. doi:https://doi.org/10.1182/blood-2009-09-243790.
- Peyvandi F, Palla R, Lotta LA. et al. ADAMTS‐13 assays in thrombotic thrombocytopenic purpura. J Thromb Haemost. 2010;8:631640. doi:https://doi.org/10.1111/j.1538-7836.2010.03761.x.
- Sun L, Mack J, Li A, et al. Predictors of relapse and efficacy of rituximab in immune thrombotic thrombocytopenic purpura. Blood Adv. 2019;3(9):1512–1518.doi:https://doi.org/10.1182/bloodadvances.2019031039.
- Al-Nouri ZL, Reese JA, Terrell DR, et al. Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood. 2015 Jan 22;125(4):616–618. doi:https://doi.org/10.1182/blood-2014-11-611335.
- Hrdinová J, D’Angelo S, NAG G, et al. Dissecting the pathophysiology of immune thrombotic thrombocytopenic purpura: interplay between genes and environmental triggers. Haematologica. 2018;103(7):1099‐1109.doi:https://doi.org/10.3324/haematol.2016.151407.
- Ramos-Casals M, Brahmer JR, Callahan MK, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020;6(1):38. doi:https://doi.org/10.1038/s41572-020-0160-6. Published May 7, 2020.
- Youssef A, Kasso N, Torloni AS, et al. Thrombotic thrombocytopenic purpura due to checkpoint inhibitors. Case Rep Hematol. 2018;2018:2464619. doi:https://doi.org/10.1155/2018/2464619. Published December 20, 2018.
- Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol. 2009;9:271–285. doi:https://doi.org/10.1038/nri2526.
- Perez-Alvarez R, Pérez-de-Lis M, Ramos-Casals M. BIOGEAS study group biologics-induced autoimmune diseases. Curr Opin Rheumatol. 2013;25:56–64. doi:https://doi.org/10.1097/BOR.0b013e32835b1366.
- Atzeni F, Talotta R, Salaffi F. et al. Immunogenicity and autoimmunity during anti-TNF therapy. Autoimmun Rev. 2013;12:703–708. doi:https://doi.org/10.1016/j.autrev.2012.10.021.
- Vaz JL, Fernandes V, Nogueira F, et al. Infliximab-induced autoantibodies: a multicenter study. Clin Rheumatol. 2016;35(2):325–332.doi:https://doi.org/10.1007/s10067-015-3140-6.
- De Bandt M, Sibilia J, Le Loët X, et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther. 2005;7(3):R545–R551.doi:https://doi.org/10.1186/ar1715.